Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Change in Receivables (2024 - 2025)

Indivior Pharmaceuticals (INDV) has 2 years of Change in Receivables data on record, last reported at $18.0 million in Q3 2025.

  • For Q3 2025, Change in Receivables rose 300.0% year-over-year to $18.0 million; the TTM value through Sep 2025 reached -$6.0 million, changed N/A, while the annual FY2023 figure was $33.0 million, N/A changed from the prior year.
  • Change in Receivables reached $18.0 million in Q3 2025 per INDV's latest filing, up from -$4.0 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $18.0 million in Q3 2025 and bottomed at -$11.0 million in Q1 2025.